Revelation Biosciences, Inc. (REVB)

Revelation Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6.54	11.99	5.25	1.27	4.49
Cash & Short-Term Investments	6.54	11.99	5.25	1.27	4.49
Cash Growth	-53.26%	128.28%	312.09%	-71.62%	-
Prepaid Expenses	0.12	0.08	0.07	0.64	0.13
Other Current Assets	-	0.07	0.09	-	-
Total Current Assets	6.66	12.15	5.41	1.91	4.62
Property, Plant & Equipment	0.08	0.07	0.09	0.13	-
Total Assets	6.74	12.21	5.5	2.04	4.62
Accounts Payable	3.13	1.36	0.55	0.6	0.87
Accrued Expenses	0.93	1.15	0.99	1.53	0.34
Current Portion of Leases	-	-	-	0.02	-
Other Current Liabilities	0	3.05	2.91	-	-
Total Current Liabilities	4.07	5.56	4.45	2.14	1.21
Total Liabilities	4.07	5.56	4.45	2.14	1.21
Common Stock	0	0	0	0	0
Additional Paid-In Capital	41.45	32.11	26.4	14.42	5.54
Retained Earnings	-38.78	-25.47	-25.35	-14.52	-2.53
Total Common Equity	2.67	6.65	1.05	-0.1	3.01
Shareholders' Equity	2.67	6.65	1.05	-0.1	3.41
Total Liabilities & Equity	6.74	12.21	5.5	2.04	4.62
Total Debt	-	-	-	0.02	-
Net Cash (Debt)	6.54	11.99	5.25	1.26	4.49
Net Cash Growth	-53.26%	128.28%	317.57%	-72.00%	-
Net Cash Per Share	4.61	52.45	72.37	-	-
Filing Date Shares Outstanding	4.29	1.63	0.15	0.01	-
Total Common Shares Outstanding	4.29	0.26	0.02	0.07	-
Working Capital	2.59	6.58	0.96	-0.23	3.41
Book Value Per Share	0.62	25.13	46.24	-1.51	-
Tangible Book Value	2.67	6.65	1.05	-0.1	3.01
Tangible Book Value Per Share	0.62	25.13	46.24	-1.51	-
Machinery	0.17	0.13	0.13	0.13	-

Source: S&P Capital IQ. Standard template. Financial Sources.